Biotechnology R&D Specialist

PolTREG·
Unknown
2w ago
Full-timeMidResearch and DevelopmentUnknownUnknownPhD
Market Rate — Biochemists and Biophysicists
25th
$70K
Median
$107K
75th
$144K

BLS 2024 data (national)

Description

Analysis of results using bioinformatics and biostatistical tools, as well as preparation of reports and publications based on the obtained data; Ongoing participation in the production and quality control of cellular preparations developed by the Company; Maintaining laboratory readiness for ongoing projects; Day-to-day administrative support of the laboratory within the scope of ongoing projects; Performing assigned tasks related to the qualification and validation of company laboratory equipment and systems; Receiving and supervising materials and reagents; Supervision of medical waste management; Data protection, including patient personal data, in accordance with laboratory procedures; Direct supervision of proper task execution; Participation in the preparation of laboratory documentation.

Requirements

Higher education in medical, biological, or biotechnological sciences; a PhD in medical biotechnology will be an asset; Experience in creating and transfecting prokaryotic and eukaryotic cells with viral vectors is desirable; Experience with non-viral vectors is welcome; Experience in molecular biology techniques; Practical knowledge of flow cytometry; Experience working with human cells or tissues (primary cultures and cell lines) — required; Experience in an immunology laboratory, a pharmaceutical production facility specializing in biological or cellular preparations, or in blood donation and transfusion units; Preferable familiarity with bioinformatics ‘big data’ analyses; Knowledge of English — at least communicative in speech and fluent in writing; Computer literacy (Office/spreadsheets); Availability; Strong willingness to learn; Openness; Ability to work in a team.
PolTREG

PolTREG

BIOTECHNOLOGY

T-reg cell growth and reperfusion treatment

LocationPoland - Gdańsk
Open Jobs2
Metabolic DiseasesCell TherapyUnknown
View Company Profile

Pipeline

ex vivo expanded CD4+CD25+CD127- regulatory T cellsPhase 2